DelveInsight's latest report reveals over 120 companies actively developing innovative therapies for influenza, including promising candidates like Moderna's mRNA-1010 vaccine and SAB Biotherapeutics' polyclonal antibody treatment. The pipeline showcases diverse therapeutic approaches, from next-generation vaccines to broad-spectrum antivirals, addressing critical needs in influenza prevention and treatment.